Cholesterol levels have been shown to be elevated in AD patients as well as the levels of cholesterol precursors in the mevalonate pathway, farnesylpyrophosphate, and geranylgeranylpyrophosphate (Hooff et al., 2010; Kolsch et al., 2010) . However, this view is by no means unanimous and other groups have found lower levels of cholesterol in AD brains (Kolsch et al., 2010; Leduc et al., 2010) , in addition to its precursors lanosterol and lathosterol (Kolsch et al., 2010) , with lower levels of its synthesizing enzyme, HMG CoA reductase (Leduc et al., 2010) . However, quantification of global cholesterol levels are not necessarily reflective of the number or distribution of lipid rafts (Leduc et al., 2010) .